scholarly journals Persistence of positive severe acute respiratory syndrome coronavirus‐2 reverse transcription–polymerase chain reaction test result for 24 days in a hospitalized asymptomatic carrier

2020 ◽  
Vol 7 (1) ◽  
Author(s):  
Takahiro Uechi ◽  
Shunsuke Nakamura ◽  
Ryo Takeshita ◽  
Kyoko Morino ◽  
Ren Mizuno ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Severe Acute Respiratory Syndrome ◽  
Reverse Transcription ◽  
Asymptomatic Carrier ◽  
Polymerase Chain Reaction Test ◽  
Chain Reaction ◽  
Reaction Test ◽  
Polymerase Chain ◽  
Chain Reaction Test ◽  
Test Result

scholarly journals Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative Patients

2020 ◽  
Author(s):  
Dustin R Long ◽  
Saurabh Gombar ◽  
Catherine A Hogan ◽  
Alexander L Greninger ◽  
Vikas O’Reilly-Shah ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Severe Acute Respiratory Syndrome ◽  
Reverse Transcription ◽  
Polymerase Chain Reaction Test ◽  
Nasopharyngeal Swab ◽  
Chain Reaction ◽  
Reaction Test ◽  
Polymerase Chain ◽  
Using Data ◽  
Chain Reaction Test

Abstract Using data for 20 912 patients from 2 large academic health systems, we analyzed the frequency of severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction test discordance among individuals initially testing negative by nasopharyngeal swab who were retested on clinical grounds within 7 days. The frequency of subsequent positivity within this window was 3.5% and was similar across institutions.

scholarly journals Computed Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test

2020 ◽  
Vol 71 (15) ◽  
pp. 850-852 ◽  
Author(s):  
Junqing Xu ◽  
Ruodai Wu ◽  
Hua Huang ◽  
Weidong Zheng ◽  
Xinling Ren ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Real Time ◽  
Reverse Transcription ◽  
Polymerase Chain Reaction Test ◽  
Chain Reaction ◽  
Computed Tomographic ◽  
Negative Results ◽  
Reaction Test ◽  
Polymerase Chain ◽  
Chain Reaction Test

Abstract We reported computed tomographic (CT) imaging findings of 3 patients with coronavirus disease 2019 (COVID-19) pneumonia with initially negative results before CT examination and finally confirmed positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time reverse-transcription polymerase chain reaction assay.

Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease

2012 ◽  
Vol 136 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Lawrence J Jennings ◽  
Frederick A Smith ◽  
Kevin C Halling ◽  
Diane L Persons ◽  
Suzanne Kamel-Reid ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Minimal Residual Disease ◽  
Reverse Transcription ◽  
Residual Disease ◽  
Polymerase Chain Reaction Test ◽  
Chain Reaction ◽  
Reaction Test ◽  
Polymerase Chain ◽  
Chain Reaction Test ◽  
Minimal Residual

Context.—Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration–approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. Objective.—To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. Design.—To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Results.—Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Conclusions.—Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.

Sign in / Sign up

Export Citation Format

Share Document